-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Assumes Coherus Oncology at Buy, Announces Price Target of $7

Benzinga·10/29/2026 13:19:51
Listen to the news
HC Wainwright & Co. analyst Swayampakula Ramakanth assumes Coherus Oncology (NASDAQ:CHRS) with a Buy rating and announces Price Target of $7.